AVRX Avalon Pharmaceuticals (MM)

GERMANTOWN, Md., August 1 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX) today announced that it is scheduled to release financial results for the second quarter of 2007, on Wednesday, August 8, 2007 after the close of the U.S. financial markets. The Company will also host a conference call on Thursday, August 9, 2007 at 8:00 a.m. Eastern Daylight Savings Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet from the investor section of the Company's website or by dialing the numbers listed below. Conference Call Details: ------------------------ Dial-In: (866) 770-7129 (U.S.) (617) 213-8067 (International) Passcode: 95694420 Webcast: Please go to: http://www.avalonrx.com/, Investor Relations/ Upcoming Presentations, within 15 minutes prior to the call and select the webcast link. The conference call replay will be available through September 30, 2007. About Avalon Pharmaceuticals Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon's lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora pathways, discovery programs for inhibitors of the survivin and Myc pathways and partnerships with Merck, MedImmune, Medarex, and Novartis. AvalonRx(R) is the company's proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable". Avalon is headquartered in Germantown, Md. DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: C. Eric Winzer, Executive Vice President and Chief Financial Officer of Avalon Pharmaceuticals, +1-301-556-9900, fax, +1-301-556-9910, Web site: http://www.avalonrx.com/

Copyright